HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Signals CBD Interest With Agreement For Potential Australian Launch

Executive Summary

GSK will evaluate the launch potential in Australia of a non-prescription CBD product currently being studied as a short-term treatment for sleep disturbances. The firm also has first refusal to negotiate the rights to market the product – developed by Cann Group – in other countries around the world.

You may also be interested in...



Why Spin Out? IQVIA Consumer Health On The Standalone Trend In OTC

Greater flexibility, a higher tolerance to risk, longer investment time-lines and access to a wider pool of next generation talent are some of the benefits to consumer health businesses when separating from their pharma parents, according to IQVIA Consumer Health. 

GSK Consumer Split Set For July, With Emerging Markets And Switch To Drive Growth

GSK will spin-off its consumer health business in July under the name Haleon. The standalone operation expects to outpace market growth rates by expanding in emerging markets, tapping into consumer demand for more natural products and delivering two Rx-to-OTC switches in the US.

Stada's Nature's Aid Launches Sustainable Supplements In UK, Frustrated At CBD Delays

HBW Insight catches up with Nature's Aid managing director Chris Morrey to talk about the firm's new sustainable dietary supplment range, Wild Earth, as well as the challenges posed by the UK's new regulstory regime for CBD novel foods. 

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152391

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel